Robert Young

Professor

Simon Fraser University

Canada

Research Interests

Explore related searches

Professors in Canada

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Robert Young is a Professor at Simon Fraser University in Canada. His research focuses on the development of novel therapeutic agents for inflammatory diseases, cancer treatment, and viral infections, as highlighted in his recent articles. He has contributed to advancements in the field of drug discovery, particularly in relation to gastrointestinal and osteogenic diseases, as well as SARS-CoV-2 protease inhibitors. Professor Young's work emphasizes the intersection of medicinal chemistry and molecular pharmacology.

Articles (13)

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (5)

Fabio M. V. Rossi

The University of British Columbia

CANADA

View details

François Jean

The University of British Columbia

CANADA

View details

Mohamed-Nur Abdallah

Adjunct Associate Professor

University of Detroit Mercy

UNITED STATES

View details

Mano Joseph MATHEW

Head of Masters in Bioinformatics & Biology department

FRANCE

View details

Karen Chan

The University of British Columbia

CANADA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Robert Young

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Development of novel GI-centric prostaglandin E2 receptor type 4 (EP4) agonist prodrugs as treatment for ulcerative colitis and other intestinal inflammatory diseases

Characterization of novel small molecule inhibitors of estrogen receptor-activation function 2 (ER-AF2)

A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants

Large-Scale Virtual Screening for the Discovery of SARS-CoV-2 Papain-like Protease (PLpro) Non-covalent Inhibitors

Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo

A protocol for identifying the binding sites of small molecules on the cystic fibrosis transmembrane conductance regulator (CFTR) protein

Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer

E-type prostanoid receptor 4 drives resolution of intestinal inflammation by blocking epithelial necroptosis

Identification of binding sites for ivacaftor on the cystic fibrosis transmembrane conductance regulator

Design, Synthesis, Pharmacokinetics, and Biodistribution of a Series of Bone-Targeting EP4 Receptor Agonist Prodrugs for Treatment of Osteoporosis and Other Bone Conditions

Effects of treatment with a bone-targeted prostaglandin E2 receptor 4 agonist C3 (Mes-1007) in a mouse model of severe osteogenesis imperfecta

Improved bone regeneration using bone anabolic drug conjugates (C3 and C6) with deproteinized bovine bone mineral as a carrier in rat mandibular defects

Achieving enhanced bone regeneration using monetite granules with bone anabolic drug conjugates (C3 and C6) in rat mandibular defects

Collaborators (5)

Fabio M. V. Rossi

François Jean

Mohamed-Nur Abdallah

Mano Joseph MATHEW

Karen Chan

Make your next move.